Pharmacokinetics of levodopa

Journal of Neurology

Volumn 257, Issue SUPPL. 2, 2010, Pages

  Contin, Manuela ^a   Martinelli, Paolo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Levodopa; Parkinson's disease; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINO ACID DECARBOXYLASE; BENSERAZIDE; CARBIDOPA; ENTACAPONE; LEVODOPA; TOLCAPONE; ANTIPARKINSON AGENT;

AREA UNDER THE CURVE; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; MAXIMUM PLASMA CONCENTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DIET; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; INTESTINE ABSORPTION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTIPARKINSON AGENTS; HUMANS; INTESTINAL ABSORPTION; LEVODOPA; PARKINSON DISEASE;

EID: 79953167914     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5728-8     Document Type: Conference Paper

References (51)

1. Astarloa R, Mena MA, Sanchez V, de la Vega L, de Yebenes JG (1992) Clinical pharmacokinetic effects of a diet rich of insoluble fiber on Parkinson disease. Clin Neuropharmacol 15:375-380
2. Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Tonello C, Zoni E, Martinelli P (1987) Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients. Clin Neuropharmacol 10:527-537 (Pubitemid 17167170)
3. Carter JH, Nutt JG, Woodward WR (1992) The effect of exercise on levodopa absorption. Neurology 2:2042-2045
4. Cedarbaum JM (1989) The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 12:147-166
5. Committee on Dietary Allowances Food and Nutrition Board (ed) (1989) Recommended dietary allowances. National Academy Press, Washington, DC
6. Contin M, Riva R, Martinelli P, Procaccianti G, Cortelli P, Avoni P, Baruzzi A (1990) Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 13:19-28 (Pubitemid 20069410)
7. Contin M, Riva R, Martinelli P, Procaccianti G, Albani F, Baruzzi A (1991) Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease: effect on levodopa bioavailability. Clin Neuropharmacol 14:148-155
8. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A (1991) Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 41:463-466
9. Contin M, Riva R, Martinelli P, Baruzzi A (1992) Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease. Mov Disord 7:244-248
10. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1993) Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 43:367-371 (Pubitemid 23060272)
11. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1994) Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 44:1287-1292 (Pubitemid 24232231)
12. Contin M, Riva R, Martinelli P, Triggs EJ, Albani F, Baruzzi A (1996) The rate of motor response to oral levodopa and the clinical progression of Parkinson's disease. Neurology 46:1055-1058 (Pubitemid 26134651)
13. Contin M, Riva R, Albani F, Baruzzi A (1996) Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 30:463-481 (Pubitemid 26175755)
14. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1999) Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol 22:351-355
15. Contin M, Riva R, Martinelli P, Albani F, Avoni A, Baruzzi A (2001) Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach. Ther DrugMonit 23:621-629 (Pubitemid 33086489)
16. Contin M, Martinelli P, Scaglione C, Avoni P, Albani F, Riva R, Baruzzi A (2008) The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease. Clin Neuropharmacol 31:267-271
17. Deleu D, Jacob P, Chand P, Sarre S, Colwell A (2006) Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 12:897-898
18. Dingemanse J, Jorga K, Zurcher G, Schmitt M, Sedek G, Da Prada M, Van Brummelen P (1995) Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253-262
19. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987) Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 21:370-376 (Pubitemid 17053274)
20. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 24:366-371
21. Gancher ST, Nutt JG, Woodward WR (1987) Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients. Neurology 37:940-944 (Pubitemid 17081066)
22. Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27:135-206
23. Guttman M, Leger G, Cedarbaum JM, Reches A, Woodward W, Evans A, Diksic M, Gjedde A (1992) 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 31:638-643
24. Harder S, Baas H, Rietbrock S (1995) Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet 29:243-256
25. Harder S, Baas H, Bergemann N, Demisch L, Rietbrock S (1995) Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol 39:39-44
26. Juncos JL, Fabbrini G, Mouradian MM, Serrati C, Chase TN (1987) Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 44:1003-1005
27. Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59:1233-1250
28. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 318:876-881
29. Kompoliti K, Adler CH, Raman MS, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG (2002) Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 58:1418-1422 (Pubitemid 34507176)
30. Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, Carter JH, Shoulson I (1988) Duodenal and gastric delivery of levodopa in Parkinsonism. Ann Neurol 23:589-595
31. Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS (1986) Inhibition of l-(18F) fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20:258-262 (Pubitemid 16044213)
32. Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A (2003) Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurol Sci 24:192-193 (Pubitemid 37304308)
33. Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N (1975) Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 25:1029-1034
34. Muhlack S, Welnic J, Woitalla D, Muller T (2007) Exercise improves efficacy of levodopa in patients with Parkinson's disease. Mov Disord 15:427-430 (Pubitemid 46569706)
35. Nutt JG, Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7:35-49 (Pubitemid 14138567)
36. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 310:483-488 (Pubitemid 14189988)
37. Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36:739-744 (Pubitemid 16056209)
38. Nutt JG (1987) On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 22:535-540
39. Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 21:584-588 (Pubitemid 17081194)
40. Nutt JG, Gancher ST, Woodward WR (1988) Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 38:1553-1557
41. Nutt JG (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40:340-345
42. Nutt JG, Holford NHG (1996) The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 39:561-573 (Pubitemid 26143594)
43. Nutt JG, Carter JH, Lea ES, Sexton GJ (2002) Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 51:686-693 (Pubitemid 34568846)
44. Nyholm D (2006) Pharmacokinetic optimisation in the treatment of Parkinson 's Disease. An update. Clin Pharmacokinet 45:109-136
45. Paalzow GHM, Paalzow LK (1986) L-dopa: how it may exacerbate parkinsonian symptoms. TIPS 9:15-19
46. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A (2006) Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurology 66:1824-1829 (Pubitemid 44049810)
47. Quinn N, Parkes D, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34:1131-1136 (Pubitemid 14068582)
48. Reuter I, Harder S, Engelhardt M, Baas H (2000) The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 15:862-868
49. Rivera-Calimlim L, Dujovne CA, Morgan JP, Lasagna L, Bianchine JR (1970) L-dopa treatment failure: explanation and correction. Br Med J 4:93-94
50. Sage JI, Schuh L, Heikkila RE, Duvoisin RC (1988) Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin Neuropharmacol 11:36-44 (Pubitemid 18039432)
51. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36:759-764